Preclinical Translational Cancer Research Program

临床前转化性癌症研究计划-摘要 斯蒂芬森癌症中心临床前转化性癌症研究(PTCR)计划的目标 (SCC)是促进和加速科学发现和思想的发展，以改善 癌症的预防、诊断和治疗。PTCR成员代表着广泛的跨学科专业知识， 从阐明肿瘤发生的基本机制到进行临床前翻译研究，创造了一个 为思想的产生和翻译创造良好的环境。该计划的具体目标是：1)发现 调节肿瘤生长、进展和治疗反应的细胞机制；2)确定 肿瘤细胞-间质相互作用导致肿瘤进展和转移的功能机制； 以及3)为增强癌症的纳米材料和成像技术开发新的工具和应用 检测、反应预测和处理。 PTCR计划的亮点包括：1)基本发现和翻译的高度互动团队 组织起来推进具体目标的科学家；2)一支强大的基础发现研究人员团队， 俄克拉荷马医学研究基金会高影响力出版物和同行评议资助记录 (OMRF)，SCC建议的联盟合作伙伴；3)与纳米材料的综合和协作研究 和OU Norman的成像调查人员；4)访问SCC共享资源，提供最先进的 支持项目科学的技术和服务；5)以疾病现场为重点的跨学科研究 在SCC发展基金的支持下，结直肠癌和胰腺癌的团队正在开发多种 PI拨款申请；以及6)NIH资助的生物医学中心强调的对指导的强烈关注 卓越研究奖P20奖。 PTCR方案有46名成员，代表19个部门和两个机构(OU和OMRF)， 说明了它的跨学科专业知识。它还具有高度的协作性：在资助的15个PTCR试点项目中 在过去两年中，10个方案内部协作，7个方案间协作。截至12月31日， 2016年，计划成员每年获得6,525,844美元的NCI和其他与癌症相关的同行评审 支持(直接成本)。NCI资金(2,915,115美元)占同行审查资金的44.7%，强调 该项目的重点是癌症。年度PTCR项目资金总额为9,101,794美元(直接成本)。对于五年的 在报告所述期间(2012-2016)，PTCR计划成员发表了446篇同行评议文章，其中16.4% 包括方案内，6.1%包括方案间，69.7%包括机构间 合作者。2016年，方案间出版物增加到14.9%，突出了不断增长的数量 正在与妇科癌症(GC)和癌症预防和控制(CPC)合作 程序。

PRECLINICAL TRANSLATIONAL CANCER RESEARCH PROGRAM – ABSTRACT The goal of the Preclinical Translational Cancer Research (PTCR) program at the Stephenson Cancer Center (SCC) is to promote and accelerate scientific discovery and development of ideas in order to improve the prevention, diagnosis and treatment of cancer. PTCR members represent broad transdisciplinary expertise, from elucidating basic mechanisms of tumorigenesis to conducting preclinical translational research, creating a robust environment for the generation and translation of ideas. The program Specific Aims are: 1) to discover cellular mechanisms that regulate tumor growth, progression and response to therapy; 2) to determine the functional mechanisms underlying tumor cell-stroma interactions leading to tumor progression and metastasis; and 3) to develop novel tools and applications for nanomaterial and imaging technologies that enhance cancer detection, response prediction and treatment. Highlights of the PTCR program include: 1) highly interactive teams of basic discovery and translational scientists organized to advance specific aims; 2) a strong team of basic discovery researchers with a track record of high-impact publications and peer-reviewed funding at the Oklahoma Medical Research Foundation (OMRF), the SCC's proposed consortium partner; 3) integrated and collaborative research with nanomaterials and imaging investigators at OU Norman; 4) access to SCC shared resources, which provide state-of-the-art technologies and services to support program science; 5) disease-site focused transdisciplinary research teams in colorectal and pancreatic cancers, supported by SCC developmental funds, that are developing multi- PI grant applications; and 6) a strong focus on mentoring highlighted by an NIH-funded Center of Biomedical Research Excellence P20 grant. The PTCR program has 46 members that represent 19 departments and two institutions (OU and OMRF), illustrating its transdisciplinary expertise. It is also highly collaborative: of the 15 PTCR pilot projects funded over the past two years, 10 have intra- and seven have inter-programmatic collaborations. As of December 31, 2016, program members were awarded $6,525,844 in annual NCI and other peer-reviewed cancer-related support (direct cost). NCI funding ($2,915,115) accounts for 44.7% of the peer-reviewed funding, highlighting the program's cancer focus. Total annual PTCR program funding is $9,101,794 (direct cost). For the five-year reporting period (2012-2016), PTCR program members published 446 peer-reviewed articles, of which 16.4% included intra-programmatic, 6.1% included inter-programmatic, and 69.7% included inter-institutional collaborators. For 2016, inter-programmatic publications increased to 14.9%, highlighting the growing number of collaborations underway with the Gynecologic Cancers (GC) and Cancer Prevention and Control (CPC) programs.